Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com CIN No.,124230MH1990PLC058071.

PAF	RT -1			Rs. In Lakh	S		
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2015							
SI.	Particulars	Quarter Ended 30.06.2015	Quarter Ended 31.03.2015	Quarter Ended 30.06.2014	Previous accounting year ended 31.03.2015		
		Unaudited	Unaudited	Unaudited	Audited		
1	(a) Net Sales/Income from Operations	367.14	447.46	375.39	1867.79		
	(b) Other Operating Income	0.00	12.88	0.00	12.88		
	Total Income From Operations ( Net)	367.14	460.34	375.39	1880.67		
2	Expenses						
	a. Cost of Materials Consumed	202.79	185.92	217.61	913.34		
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00		
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-48.83	-2.69	-63.72	-1.33		
	d. Employee Benfit Expenses	100.56	101.31	88.53	408.36		
	e. Depreciation and Amortisation Expense	31.47	38.18	30.29	131.23		
	f.Loss/Gain on Foreign Exchange Transactions	-0.45	0.00	0.00	-0.34		
	g. Other expenditure	91.06	111.45	86.83	376.94		
	Total Expenses	376.60	434.17	359.54	1828.20		
,	Profit from operations before Other Income and Fiance Cost (1-2)	-9.46	26.17	15.85	52.47		
4	Other Income	4.11	1.87	0.11	2.03		
	Profit before Filinance Costs (3+4)	-5.35	28.04	15.96	54.50		
(	Finance Costs	13.16	13.69	11.49	53.81		
	Profit/ Loss before Tax (5-6)	-18.51	14.35	4.47	0.69		
1		0.00	0.00	0.00	105.04		
,	Net profit (+)/Loss (-) for the period (7-8)	-18.51	14.35	4.47	-104.35		
	Paid-up equity share capital ( Face Value of Rs. 10/- each)	992.58	992.58	972.50			
1	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				-463.48		
1:	2 Earnings Per Share (EPS) - Face Value of Share Rs. 10/ each ( Not Annualised)						
	- Basic and diluted	-0.19	0.14	0.04	-1.04		

## NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com CIN No.,124230MH1990PLC058071.

Select Information for the Quarter Ended 30.06.2015							
SI. No.	Particulars	Quarter Ended 30.06.2015	Quarter Ended 31.03.2015	Quarter Ended 30.06.2014	Previous accounting year ended 31.03.2015		
Α	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	-No. of shares	6596069	6596069	6596069	6596069		
	-Percentage of shareholding	65.96	65.96	65.96	65.96		
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	-No. of shares	Nil	Nil	Nil	Nil		
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	Nil	Nil	Nil	Nil		
	- Percentage of shares (as a% of the total share capital of the Company)	Nil	Nil	Nil	Nil		
b)	Non-encumbered						
	-No. of shares	3404631	3404631	3404631	3404631		
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00	100.00	100.00	100.00		
	- Percentage of shares (as a% of the total share capital of the Company)	34.04	34.04	34.04	34.04		

PARTICULARS	Quarter Ended 30.06.2015	
B. INVESTORS COMPLAINTS		
Pending at the beginning of the Quarter	Nil	
Received during the quarter	02	
Disposed off during the quarter	02	
Remaining unresolved at the end of the quarter	Nil	

## Notes:

- 1) The above Unaudited Fianacial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 31.07.2015. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 30.6.2015.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah **Managing Director** 

Date: 31.07.2015 Place:Ankleshwar

STATEMENT OF ASSETS AND LIABILITIES	30.06.2015 Un audited	31.03.2015 (Audited)
1. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital		
(b) Reserves & Surplus	992.5 -481.9	002.0
(2) Share Application money pending allotment		
(2) Non - Current Liabilities		-
(a) Long Term borrowings	740.00	
(b) Long Term provisions	748.93	748.93
(3) Current Liabilities		
(a) Short Term borrowings		
(b) Trade payables	47.33	01.02
© Other current liabilities	312.38	
(d) Short Term provisions	102.60 100.07	00.01
TOTAL	1821.89	
II. ASSETS		
(1) Non -current assets		
(a) Fixed Assets		
(i) Tangible assets	000.04	
(ii) Capital Work in Progress	832.91	861.06
(b) Non Current investments	0.00	
Deferred tax assets (net)	0.86 122.03	1
d) Long Term Loans and Advances	69.33	
(2) Current Assets		
a) Current investments	139	
b) Inventories	365.73	050.00
Trade Receivables	303.68	200.00
d) Cash & cash equivalents	47.94	
e) Short Term Loans and advances	79.41	20.00
f) Other Current assets	79.41	52.46
	1821.89	1815.35

For Norris Medicines Limited

Vimal D Shah Managing Director

Date: 31.07.2015 Place:Ankleshwar